
Aurora Spine was issued U.S. Patent No. 10,779,954, “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use,” for DEXA Technology™ Patient-Matched Implant Technology.
This patent supports implants that match the patient’s specific bone density based on a DEXA Scan/T-score, allowing for the best bone fusion and most favorable outcome based on that patient’s bone density.
DEXA Technology was created and patented to combine the design benefits of conventional machining, 3D printing and additive implant manufacturing.
“Aurora Spine’s new DEXA Technology will provide surgeons with additional solutions in selecting the right implant for their patient,” said Trent Northcutt, CEO of Aurora Spine. “The DEXA opportunity represents our continued commitment to delivering best-in-class implants that enable our surgeon partners to overcome common osteoporosis challenges faced in traditional procedures. We will be commercializing this technology in the coming months.”
Aurora Spine was issued U.S. Patent No. 10,779,954, “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use,” for DEXA Technology™ Patient-Matched Implant Technology.
This patent supports implants that match the patient’s specific bone density based on a DEXA Scan/T-score, allowing for the best bone fusion and most...
Aurora Spine was issued U.S. Patent No. 10,779,954, “Body Density Scan Result-Matched Orthopedic Implants and Methods of Use,” for DEXA Technology™ Patient-Matched Implant Technology.
This patent supports implants that match the patient’s specific bone density based on a DEXA Scan/T-score, allowing for the best bone fusion and most favorable outcome based on that patient’s bone density.
DEXA Technology was created and patented to combine the design benefits of conventional machining, 3D printing and additive implant manufacturing.
“Aurora Spine’s new DEXA Technology will provide surgeons with additional solutions in selecting the right implant for their patient,” said Trent Northcutt, CEO of Aurora Spine. “The DEXA opportunity represents our continued commitment to delivering best-in-class implants that enable our surgeon partners to overcome common osteoporosis challenges faced in traditional procedures. We will be commercializing this technology in the coming months.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.